About von Willebrand Disease: What Is von Willebrand Disease?

A common hereditary bleeding disorder

According to the Centers for Disease Control and Prevention (CDC), von Willebrand disease (VWD) is the most common bleeding disorder, affecting 1% of the US population or about 1.4 million Americans. VWD is equally likely to affect men and women.1

People who have VWD take longer than normal to stop bleeding. Why? A protein in the blood, called von Willebrand factor (VWF), helps clots form. People with von Willebrand disease don’t have enough von Willebrand factor or their VWF might not work properly.

Many people who have von Willebrand disease do not even know it. They might have key symptoms, but might mistakenly think those signs of VWD are normal or untreatable.

Common signs and symptoms of VWD

  • Easy bruising
  • Frequent or prolonged nosebleeds
  • Menorrhagia (heavy or prolonged menstrual periods)
  • Prolonged bleeding following injury, childbirth, or surgery
  • Prolonged bleeding during dental procedures

If you’re experiencing any of these signs or symptoms, please tell your nurse or doctor immediately.


The different types of VWD

VWD Type VWF Levels % VWD patients affected Symptoms
Type 1 Low VWF levels About 60% - 80% The most common form of the disease; symtoms are usually mild
Type 2 Normal VWF levels but VWF does not work correctly About 15% - 30% Usually causes moderate symptoms, with occasional severe symptoms
Type 3 Little or no VWF About 5% - 10% The least common form of VWD, but usually causes the most severe symptoms
  • Types of VWD are inherited differently
    • Types 1 and 2 are inherited in a dominant pattern: only one of a child’s parents has to have VWD to pass it to their child
    • Type 3 is inherited in a recessive pattern: both parents must have VWD to pass it to their child

www.MySourceCSL.com provides valuable information and resources for people with VWD and their caregivers

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P® is approved to treat and prevent bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P also treats spontaneous or trauma-induced bleeding episodes in adults and children with von Willebrand disease (VWD) and prevents excessive bleeding during and after surgery in patients with mild, moderate or severe VWD. Humate-P is not known to prevent spontaneous bleeding episodes.

Do not take Humate-P if you have had extreme sensitivity or an allergic response to antihemophilic or von Willebrand factor preparations. Your doctor will monitor you for events related to abnormal blood clotting.

Humate-P is made from human blood and could contain infectious agents. The risk that these agents may transmit disease cannot be completely eliminated, but has been reduced by screening plasma donors and testing donated plasma for certain viruses, and by inactivating and/or removing viruses during manufacturing.

In studies, more than 5% of patients reported the following adverse reactions to Humate-P: allergic/anaphylactic reactions, including hives, chest tightness, rash, itching, and swelling. The most common adverse reactions after surgery were bleeding at the wound or infusion site, and nosebleeds.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Young adults sitting on a bench interior page Mom and child walking together interior page Father and son playing soccer interior page Father and son flying a kite interior page

© CSL Behring 2018. The product information on this site is intended for US residents only. HUM / 10-11-0010(1) 8/2015

References

  1. Centers for Disease Control and Prevention (CDC). Facts about von Willebrand disease. http://www.cdc.gov/ncbddd/vwd/facts.html Published March 20, 2015. Accessed April 27, 2015.